SCHEMBL18486272

SCHEMBL18486272

O=c1[nH]c(=O)n([C@@H]2O[C@H](COP(=O)(OC[C@H]3O[C@@H](n4cc(/C=C/c5ccccc5)c(=O)[nH]c4=O)[C@H](O)[C@@H]3O)OC[C@H]3O[C@@H](n4cc(/C=C/c5ccccc5)c(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)cc1/C=C/c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
P2RY2 P41231 4/20 0.73
TK2 O00142 2/20 0.57
DNPH1 O43598 1/20 0.54
IMPDH2 P12268 1/20 0.53
P2RY6 Q15077 7/20 0.52
P2RY14 Q15391 3/20 0.52
NT5E P21589 1/20 0.52
P2RY12 Q9H244 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16871787 0.93 P2RY2 (0.75) P2RY2TK2DNPH1IMPDH2P2RY6
SCHEMBL17369140 0.93 P2RY2 (0.75) P2RY2TK2DNPH1IMPDH2P2RY6
SCHEMBL16871721 0.83 P2RY2 (0.54) P2RY2TK2IMPDH2P2RY6P2RY12
SCHEMBL21465066 0.81 TK2 (0.72) P2RY2TK2DNPH1P2RY6P2RY14
SCHEMBL21465110 0.81 TK2 (0.72) P2RY2TK2DNPH1P2RY6P2RY14
SCHEMBL4959499 0.81 TK2 (0.72) P2RY2TK2DNPH1P2RY6P2RY14
SCHEMBL7040216 0.79 DNPH1 (0.68) P2RY2TK2DNPH1P2RY6P2RY14
SCHEMBL17363852 0.78 DNPH1 (0.63) DNPH1P2RY6P2RY14NT5E
SCHEMBL16871723 0.78 P2RY2 (0.56) P2RY2TK2DNPH1IMPDH2P2RY12
SCHEMBL14948888 0.77 TK2 (0.54) P2RY2TK2DNPH1P2RY6P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 P2RY2 2497/4885TK2 580/4885DNPH1 2051/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 P2RY2 2562/4885TK2 592/4885DNPH1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.